Sign in

CIK 0001636282

  • Large accelerated filer

Spyre Therapeutics, Inc.

Sign in to watch
Ticker
SYRE
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
464312787
Phone
+1 617-651-5940
Business address
221 CRESCENT STREET, BUILDING 23, SUITE 105, WALTHAM, MA, 02453
Former names
Aeglea BioTherapeutics, Inc.
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$12,349,597
in 6 filings, $12.3M under 10b5-1 plans

Net −$12,349,597. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Reading 21 more Form 4s from the SEC; this list fills in as they're read.

Date Insider Transaction Shares Price Value Owned after
2023-06-22 Alspaugh Jonathan President and CFO Grant or award · Employee Stock Option (right to buy) +19,787,969 19,787,969
2023-02-23 Alspaugh Jonathan Chief Financial Officer Grant or award · Employee Stock Option (right to buy) +640,000 640,000
2022-08-23 Alspaugh Jonathan Chief Financial Officer Grant or award · Employee Stock Option (right to buy) +130,000 130,000
2022-03-11 Alspaugh Jonathan Chief Financial Officer Purchase +75,000 $2.08 $156K 165,372
2022-02-17 Alspaugh Jonathan Chief Financial Officer Grant or award · Employee Stock Option (right to buy) +170,000 170,000
2021-12-09 Alspaugh Jonathan Chief Financial Officer Purchase +50,000 $3.72 $186K 90,372
2021-08-18 Alspaugh Jonathan Chief Financial Officer Purchase +7,200 $6.72 $48K 40,372
2021-08-17 Alspaugh Jonathan Chief Financial Officer Purchase +23,392 $6.50 $152K 33,172
2021-08-16 Alspaugh Jonathan Chief Financial Officer Purchase +9,780 $6.37 $62K 9,780
2021-07-06 Alspaugh Jonathan Chief Financial Officer Grant or award · Employee Stock Option (right to buy) +160,000 160,000

Page 1 of 1 · 10 trades